SECURITIES PURCHASE AGREEMENT



 Exhibit 10.1 
  
 ICORIA, INC. 
  
 SECURITIES PURCHASE AGREEMENT 
  
 October 19, 2004 







 TABLE OF CONTENTS 
  

							
	 	  	 	  	Page


	1.	  	Agreement to Sell and Purchase	  	1
			
	2.	  	Fees and Warrant	  	2
			
	3.	  	Closing, Delivery and Payment.	  	2
	 	  	3.1	  	Closing	  	2
	 	  	3.2	  	Delivery	  	2
			
	4.	  	Representations and Warranties of the Company	  	3
	 	  	4.1	  	Organization, Good Standing and Qualification	  	3
	 	  	4.2	  	Subsidiaries	  	3
	 	  	4.3	  	Capitalization; Voting Rights	  	3
	 	  	4.4	  	Authorization; Binding Obligations	  	4
	 	  	4.5	  	Liabilities	  	5
	 	  	4.6	  	Agreements; Action	  	5
	 	  	4.7	  	Obligations to Related Parties	  	5
	 	  	4.8	  	Changes	  	6
	 	  	4.9	  	Title to Properties and Assets; Liens, Etc.	  	7
	 	  	4.10	  	Intellectual Property	  	8
	 	  	4.11	  	Compliance with Other Instruments	  	8
	 	  	4.12	  	Litigation	  	8
	 	  	4.13	  	Tax Returns and Payments	  	9
	 	  	4.14	  	Employees	  	9
	 	  	4.15	  	Registration Rights and Voting Rights	  	10
	 	  	4.16	  	Compliance with Laws; Permits	  	10
	 	  	4.17	  	Environmental and Safety Laws	  	10
	 	  	4.18	  	Valid Offering	  	10
	 	  	4.19	  	Full Disclosure	  	11
	 	  	4.20	  	Insurance	  	11
	 	  	4.21	  	SEC Reports	  	11
	 	  	4.22	  	Listing	  	11
	 	  	4.23	  	No Integrated Offering	  	11
	 	  	4.24	  	Stop Transfer	  	12
	 	  	4.25	  	Dilution	  	12
			
	5.	  	Representations and Warranties of the Purchaser	  	12
	 	  	5.1	  	No Shorting	  	12
	 	  	5.2	  	Requisite Power and Authority	  	13
	 	  	5.3	  	Investment Representations	  	13
	 	  	5.4	  	Purchaser Bears Economic Risk	  	13
	 	  	5.5	  	Acquisition for Own Account	  	14
	 	  	5.6	  	Purchaser Can Protect Its Interest	  	14
	 	  	5.7	  	Accredited Investor	  	14
	 	  	5.8	  	Legends	  	14
			
	6.	  	Covenants of the Company	  	15
	 	  	6.1	  	Stop-Orders	  	15

  

 i 









							
	 	  	6.2	  	Listing	  	15
	 	  	6.3	  	Market Regulations	  	15
	 	  	6.4	  	Reporting Requirements	  	15
	 	  	6.5	  	Use of Funds	  	16
	 	  	6.6	  	Access to Facilities	  	16
	 	  	6.7	  	Taxes	  	16
	 	  	6.8	  	Insurance	  	16
	 	  	6.9	  	Intellectual Property	  	17
	 	  	6.10	  	Properties	  	18
	 	  	6.11	  	Confidentiality	  	18
	 	  	6.12	  	Required Approvals	  	18
	 	  	6.13	  	Reissuance of Securities	  	19
	 	  	6.14	  	Opinion	  	19
	 	  	6.15	  	Margin Stock	  	19
	 	  	6.16	  	Financing Right of First Refusal	  	19
			
	7.	  	Covenants of the Purchaser	  	19
	 	  	7.1	  	Confidentiality	  	19
	 	  	7.2	  	Non-Public Information	  	20
			
	8.	  	Covenants of the Company and Purchaser Regarding Indemnification	  	20
	 	  	8.1	  	Company Indemnification	  	20
	 	  	8.2	  	Purchaser’s Indemnification	  	20
			
	9.	  	Conversion of Convertible Note	  	20
	 	  	9.1	  	Mechanics of Conversion	  	20
			
	10.	  	Registration Rights.	  	22
	 	  	10.1	  	Registration Rights Granted	  	22
	 	  	10.2	  	Offering Restrictions	  	22
			
	11.	  	Miscellaneous	  	22
	 	  	11.1	  	Governing Law	  	22
	 	  	11.2	  	Survival	  	22
	 	  	11.3	  	Successors	  	22
	 	  	11.4	  	Entire Agreement	  	23
	 	  	11.5	  	Severability	  	23
	 	  	11.6	  	Amendment and Waiver	  	23
	 	  	11.7	  	Delays or Omissions	  	23
	 	  	11.8	  	Notices	  	23
	 	  	11.9	  	Attorneys’ Fees	  	24
	 	  	11.10	  	Titles and Subtitles	  	24
	 	  	11.11	  	Facsimile Signatures; Counterparts	  	25
	 	  	11.12	  	Broker’s Fees	  	25
	 	  	11.13	  	Construction	  	25

  

 ii 








 LIST OF SCHEDULES 
  

			
	 Capitalization and Voting Rights
	  	Schedule 4.3
		
	 Agreements; Action
	  	Schedule 4.6
		
	 Obligations to Related Parties
	  	Schedule 4.7
		
	 Changes
	  	Schedule 4.8
		
	 Tax Returns and Payments
	  	Schedule 4.13
		
	 Employees
	  	Schedule 4.14
		
	 Registration Rights and Voting Rights
	  	Schedule 4.15
		
	 Environmental and Safety Laws
	  	Schedule 4.17
		
	 Broker’s Fees
	  	Schedule 11.12

  

			
	LIST OF EXHIBITS	  	 
		
	 Form of Convertible Term Note
	  	Exhibit A
	 Form of Warrant
	  	Exhibit B
	 Form of Opinion
	  	Exhibit C
	 Form of Escrow Agreement
	  	Exhibit D

  

 iii 








 SECURITIES PURCHASE AGREEMENT 
  
 THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of October 19, 2004, by and
between Icoria, Inc., a Delaware corporation (the “Company”), and Laurus Master Fund, Ltd., a Cayman Islands company (the “Purchaser”). 
  
 RECITALS 
  
 WHEREAS, the Company has authorized the sale to the Purchaser of a Convertible Term Note (the “Note”) in the aggregate principal amount of Five
Million Dollars ($5,000,000), which Note is convertible into shares of the Company’s common stock, $0.01 par value per share (the “Common Stock”) at an initial fixed conversion price of $0.53 per share of Common Stock (“Fixed
Conversion Price”); 
  
 WHEREAS, the Company wishes to issue
warrants to the Purchaser to purchase up to 1,650,943 shares of the Company’s Common Stock (subject to adjustment as set forth therein) in connection with Purchaser’s purchase of the Note; 
  
 WHEREAS, Purchaser desires to purchase the Note and the Warrants (as defined
in Section 2) on the terms and conditions set forth herein, said Note and Warrants are further evidenced by separate agreements and additional documents, the Securities Purchase Agreement, the Funds Escrow Agreement, the Registration Rights
Agreement and the Master Security Agreement, associated with this Agreement (the “Related Agreements” or the “Documents” or the “Other Agreements”); and 
  
 WHEREAS, the Company desires to issue and sell the Note and Warrants to Purchaser on the terms and conditions set forth
herein. 
  
 AGREEMENT 
  
 NOW, THEREFORE, in consideration of the foregoing recitals and the mutual
promises, representations, warranties and covenants hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 
  
 1. Agreement to Sell and Purchase. Pursuant to the terms and conditions set forth in
this Agreement, on the Closing Date (as defined in Section 3), the Company agrees to sell to the Purchaser, and the Purchaser hereby agrees to purchase from the Company a Note in the aggregate principal amount of $5,000,000 convertible in accordance
with the terms thereof into shares of the Company’s Common Stock in accordance with the terms of the Note and this Agreement. The Note purchased on the Closing Date shall be known as the “Offering.” A form of the Note is annexed
hereto as Exhibit A. The Note will mature on the Maturity Date (as defined in the Note). Collectively, the Note and Warrant and Common Stock issuable in payment of the Note, upon conversion of the Note and upon exercise of the Warrant are referred
to as the “Securities.” 







 2. Fees and Warrant. On the Closing Date: 
  
 (a) The Company will issue and deliver to the Purchaser (i) a warrant to purchase up to 825,471 shares of
Common Stock within two years after the Closing Date in connection with the Offering, in the form of Exhibit B-1 hereto (as amended, modified or supplemented from time to time, the “Two-Year Warrant”), and (ii) a warrant to purchase up to
825,472 shares of Common Stock within five years after the Closing Date in connection with the Offering, in the form of Exhibit B-2 hereto (as amended, modified or supplemented from time to time, the “Five-Year Warrant”; the Two-Year
Warrant and the Five-Year Warrant are collectively referred to herein as the “Warrant”). The Warrant must be delivered on the Closing Date. All the representations, covenants, warranties, undertakings, and indemnification, and other rights
made or granted to or for the benefit of the Purchaser by the Company are hereby also made and granted in respect of the Warrant and shares of the Company’s Common Stock issuable upon exercise of the Warrant (the “Warrant Shares”).

  
 (b) Subject to the terms of Section 2(d)
below, the Company shall pay to Laurus Capital Management, LLC, manager of Purchaser a $175,000 closing payment, which is an amount equal to three and one-half percent (3.50%) of the aggregate principal amount of the Note. The foregoing fee is
referred to herein as the “Closing Payment.” 
  
 (c) The Company shall reimburse the Purchaser for its reasonable expenses (including legal fees and expenses) incurred in connection with the preparation and negotiation of this Agreement and the Related Agreements (as hereinafter defined),
and expenses incurred in connection with the Purchaser’s due diligence review of the Company and its Subsidiaries (as defined in Section 6.8) and all related matters. Amounts required to be paid under this Section 2(c) will be paid on the
Closing Date and shall be $39,500 for such expenses referred to in this Section 2(c). 
  
 (d) The Closing Payment and the expenses referred to in the preceding clause (c) (net of the $15,000 and other deposit(s) previously paid
by the Company) shall be paid at closing out of funds held pursuant to the Escrow Agreement (as defined below) and a disbursement letter (the “Disbursement Letter”). 
  
 3. Closing, Delivery and Payment. 
  
 3.1 Closing. Subject to the terms and conditions herein, the closing of the transactions contemplated hereby (the “Closing”), shall take place
on the date hereof, at such time or place as the Company and Purchaser may mutually agree (such date is hereinafter referred to as the “Closing Date”). 
  
 3.2 Delivery. Pursuant to the Escrow Agreement, at the Closing on the Closing Date, the Company will deliver to the
Purchaser, among other things, a Note in the form attached as Exhibit A representing the principal amount of $5,000,000 and the Two-Year Warrant and the Five-Year Warrant, each in the Purchaser’s name representing an aggregate of 1,650,943
underlying shares of Common Stock and the Purchaser will deliver to the Company, among other things, the amounts set forth in the Disbursement Letter by wire transfer. 
  

 2 








 4. Representations and Warranties of the Company. The Company hereby represents and warrants to the Purchaser as
follows. The representations and warranties are supplemented by, and subject to, the Company’s filings under the Securities Exchange Act of 1934 made prior to the date of this Agreement, collectively, the (“Exchange Act Filings”)
copies of which have been provided to the Purchaser. Such information previously disclosed in the Exchange Act Filings is not reproduced in the Schedules attached hereto. The disclosures contained herein focus exclusively on the events and
occurrences that arose during the time period from the June 30, 2004 quarterly report on Form 10-Q, filed August 16, 2004, through the date of this agreement. 
  

4.1 Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the
laws of Delaware. The Company has the corporate power and authority to own and operate its properties and assets, to execute and deliver this (i) this Agreement, (ii) the Note, the Two-Year Warrant and the Five-Year Warrant to be issued in
connection with this Agreement, (iii) the Security Agreement dated as of the date hereof between the Company and the Purchaser, (iv) the Registration Rights Agreement relating to the Securities dated as of the date hereof between the Company and the
Purchaser (as amended, modified or supplemented from time to time, the “Registration Rights Agreement”), (v) the Escrow Agreement dated as of the date hereof among the Company, the Purchaser and the escrow agent referred to therein,
substantially in the form of Exhibit D hereto (as amended, modified or supplemented from time to time, the “Escrow Agreement”) and (vi) all other agreements related to this Agreement and the Note and referred to herein (the preceding
clauses (ii) through (vi), collectively, the “Related Agreements”), to issue and sell the Note and the shares of Common Stock issuable upon conversion of the Note (the “Note Shares”), to issue and sell the Warrant and the Warrant
Shares, and to carry out the provisions of this Agreement and the Related Agreements and to carry on its business as presently conducted. The Company is duly qualified and is authorized to do business and is in good standing as a foreign corporation
in all jurisdictions, except for those jurisdictions in which the failure to do so has not had, or could not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the business, assets, liabilities, condition
(financial or otherwise), properties, operations or prospects of the Company (a “Material Adverse Effect”). 
  
 4.2 Subsidiaries. Each direct and indirect Subsidiary of the Company, the direct owner of such Subsidiary and its percentage ownership thereof, is
set forth on Schedule 4.2. For the purpose of this Agreement, a “Subsidiary” of any person or entity means (i) a corporation or other entity whose shares of stock or other ownership interests having ordinary voting power (other than
stock or other ownership interests having such power only by reason of the happening of a contingency) to elect a majority of the directors of such corporation, or other persons or entities performing similar functions for such person or entity, are
owned, directly or indirectly, by such person or entity or (ii) a corporation or other entity in which such person or entity owns, directly or indirectly, more than 50% of the equity interests at such time. 
  
 4.3 Capitalization; Voting Rights. 
  
 (a) The authorized capital stock of the Company, as of
September 30, 2004, consists of 105,000,000 shares, of which 100,000,000 are shares of Common Stock, par value $0.01 per share, 36,323,274 shares of which are issued and outstanding, and 5,000,000 are shares of preferred stock, par value $0.01 per
share, of which no shares of preferred stock are issued and outstanding. 
  

 3 








 (b) Except as disclosed on Schedule 4.3, another Schedule to this Agreement or in any
Exchange Act Filings, other than: (i) the shares reserved for issuance under the Company’s stock option plans; and (ii) shares which may be issued pursuant to this Agreement and the Related Agreements, there are no outstanding options,
warrants, rights (including conversion or preemptive rights and rights of first refusal), proxy or stockholder agreements, or arrangements or agreements of any kind for the purchase or acquisition from the Company of any of its securities. Except as
disclosed on Schedule 4.3, another Schedule to this Agreement or in any Exchange Act Filings, neither the offer, issuance or sale of any of the Note or Warrant, or the issuance of any of the Note Shares or Warrant Shares, nor the consummation of any
transaction contemplated hereby will result in a change in the price or number of any securities of the Company outstanding, under anti-dilution or other similar provisions contained in or affecting any such securities. 
  
 (c) All issued and outstanding shares of the Company’s
Common Stock: (i) have been duly authorized and validly issued and are fully paid and nonassessable; and (ii) were issued in compliance with all applicable state and federal laws concerning the issuance of securities. 
  
 (d) The rights, preferences, privileges and restrictions of
the shares of the Common Stock are as stated in the Company’s Certificate of Incorporation (the “Charter”). The Note Shares and Warrant Shares have been duly and validly reserved for issuance. When issued in compliance with the
provisions of this Agreement and the Company’s Charter, the Securities will be validly issued, fully paid and nonassessable, and will be free of any liens or encumbrances; provided, however, that the Securities may be subject to restrictions on
transfer under state and/or federal securities laws as set forth herein or as otherwise required by such laws at the time a transfer is proposed. 
  
 4.4 Authorization; Binding Obligations. All corporate action on the part of the Company, its officers and directors necessary for the authorization
of this Agreement and the Related Agreements, the performance of all obligations of the Company hereunder and under the Related Agreements at the Closing and, the authorization, sale, issuance and delivery of the Note and Warrant has been taken or
will be taken prior to the Closing. This Agreement and the Related Agreements, when executed and delivered and to the extent it is a party thereto, will be valid and binding obligations of the Company enforceable in accordance with their terms,
except: 
  
 (a) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights; and 
  
 (b) general principles of equity that restrict the availability of equitable or legal remedies. 
  

 4 








 The sale of the Note and the subsequent conversion of the Note into Note Shares are not and will not be subject to any
preemptive rights or rights of first refusal that have not been properly waived or complied with. The issuance of the Warrant and the subsequent exercise of the Warrant for Warrant Shares are not and will not be subject to any preemptive rights or
rights of first refusal that have not been properly waived or complied with. 
  
 4.5 Liabilities. The Company does not have any contingent liabilities in excess of $200,000, except current liabilities incurred in the ordinary course of business and liabilities disclosed in any Exchange Act
Filings. 
  
 4.6 Agreements; Action. Except as set forth on
Schedule 4.6 or as disclosed in any Exchange Act Filings: 
  
 (a) There are no agreements, understandings, instruments, contracts, proposed transactions, judgments, orders, writs or decrees to which the Company is a party or to its knowledge by which it is bound which may
involve: (i) obligations (contingent or otherwise) of, or payments to, the Company in excess of $200,000 (other than obligations of, or payments to, the Company arising from purchase or sale agreements entered into in the ordinary course of
business); or (ii) the transfer or license of any patent, copyright, trade secret or other proprietary right to or from the Company (other than licenses arising from the purchase of “off the shelf” or other standard products); or (iii)
provisions restricting the development, manufacture or distribution of the Company’s products or services; or (iv) indemnification by the Company with respect to infringements of proprietary rights. 
  
 (b) Since June 30, 2004, the Company has not: (i) declared
or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock; (ii) incurred any indebtedness for money borrowed or any other liabilities (other than ordinary course obligations)
individually in excess of $200,000 or, in the case of indebtedness and/or liabilities individually less than $200,000, in excess of $300,000 in the aggregate; (iii) made any loans or advances to any person not in excess, individually or in the
aggregate, of $200,000, other than ordinary advances for travel expenses; or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the ordinary course of business. 
  
 (c) For the purposes of subsections (a) and (b) above, all
indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same person or entity (including persons or entities the Company has reason to believe are affiliated therewith) shall be
aggregated for the purpose of meeting the individual minimum dollar amounts of such subsections. 
  
 4.7 Obligations to Related Parties. Except as set forth on Schedule 4.7 or in any Exchange Act filings, there are no obligations of the Company to
officers, directors, ten percent (10%) or greater stockholders or employees of the Company other than: 
  
 (a) for payment of salary for services rendered and for bonus payments; 
  

 5 








 (b) reimbursement for reasonable expenses incurred on behalf of the Company; 

 
 (c) for other standard employee benefits made generally
available to all employees (including stock option agreements outstanding under any stock option plan approved by the Board of Directors of the Company); and 
  

(d) obligations listed in the Company’s financial statements or disclosed in any of its Exchange Act Filings. 
  
 Except as described above or set forth on Schedule 4.7 or in any Exchange Act Filings, none
of the officers, directors or, to the best of the Company’s knowledge, key employees or ten percent (10%) or greater stockholders of the Company or any members of their immediate families, are indebted to the Company, individually or in the
aggregate, in excess of $200,000 or have any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a business relationship, or any firm or corporation which competes with
the Company, other than passive investments in publicly traded companies (representing less than one percent (1%) of such company) which may compete with the Company. Except as described above, no officer, director or stockholder, or any member of
their immediate families, is, directly or indirectly, interested in any material contract with the Company and no agreements, understandings or proposed transactions are contemplated between the Company and any such person. Except as set forth on
Schedule 4.7 or in any Exchange Act Filings, the Company is not a guarantor or indemnitor of any indebtedness of any other person, firm or corporation. 
  
 4.8 Changes. Since June 30, 2004, except as disclosed in any Exchange Act Filings or in Schedule 4.8 to this Agreement or to any of the Related
Agreements, there has not been: 
  
 (a) any
change in the business, assets, liabilities, condition (financial or otherwise), properties, operations or prospects of the Company, which, individually or in the aggregate, has had or could reasonably be expected to have, a Material Adverse Effect;

  
 (b) any resignation or termination of any
officer, key employee or group of employees of the Company; 
  
 (c) any material change, except in the ordinary course of business, in the contingent obligations of the Company by way of guaranty, endorsement, indemnity, warranty or otherwise; 
  
 (d) any damage, destruction or loss, whether or not covered
by insurance, which has had, or could reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect; 
  
 (e) any waiver by the Company of a valuable right or of a material debt owed to it; 
  

 6 








 (f) any direct or indirect material loans made by the Company to any stockholder,
employee, officer or director of the Company, other than advances made in the ordinary course of business; 
  
 (g) any material change in any compensation arrangement or agreement with any employee, officer, director or stockholder; 
  
 (h) any declaration or payment of any dividend or other
distribution of the assets of the Company; 
  
 (i) any labor organization activity related to the Company; 
  
 (j) any debt, obligation or liability incurred, assumed or guaranteed by the Company, except those for immaterial amounts and for current liabilities incurred in the ordinary course of business; 
  
 (k) any sale, assignment or transfer of any patents,
trademarks, copyrights, trade secrets or other intangible assets; 
  
 (l) any change in any material agreement to which the Company is a party or by which it is bound which, either individually or in the aggregate, has had, or could reasonably be expected to have, a Material Adverse
Effect; 
  
 (m) any other event or condition of
any character that, either individually or in the aggregate, has had, or could reasonably be expected to have, a Material Adverse Effect; or 
  
 (n) any arrangement or commitment by the Company to do any of the acts described in subsection (a) through (m) above. 
  
 4.9 Title to Properties and Assets; Liens, Etc. Except as set forth on
Schedule 4.9 or in any Exchange Act Filings, the Company has good and marketable title to its properties and assets, and good title to its leasehold estates, in each case subject to no mortgage, pledge, lien, lease, encumbrance or charge, other
than: 
  
 (a) those resulting from taxes which
have not yet become delinquent; 
  
 (b) minor
liens and encumbrances which do not materially detract from the value of the property subject thereto or materially impair the operations of the Company; and 
  

(c) those that have otherwise arisen in the ordinary course of business. 
  
 All facilities, machinery, equipment, fixtures, vehicles and other properties owned, leased or used by the Company are in good operating
condition and repair and are reasonably fit and usable for the purposes for which they are being used. Except as set forth on Schedule 4.9 or in any Exchange Act Filings, the Company is in compliance with all material terms of each lease to which it
is a party or is otherwise bound. 
  

 7 








 4.10 Intellectual Property. 
  
 (a) Except as disclosed in any Exchange Act Filings, the Company owns or possesses sufficient legal rights
to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes necessary for its business as now conducted and to the Company’s knowledge as presently proposed
to be conducted (the “Intellectual Property”), without any known infringement of the rights of others. There are no outstanding options, licenses or agreements of any kind relating to the foregoing proprietary rights, nor is the Company
bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes of any other
person or entity other than such licenses or agreements arising from the purchase of “off the shelf” or standard products. 
  
 (b) Except as disclosed in any Exchange Act Filings, the Company has not received any communications alleging that the Company has
violated any of the patents, trademarks, service marks, trade names, copyrights or trade secrets or other proprietary rights of any other person or entity, nor is the Company aware of any basis therefor. 
  
 (c) Except as disclosed in any Exchange Act Filings, the
Company does not believe it is or will be necessary to utilize any inventions, trade secrets or proprietary information of any of its employees made prior to their employment by the Company, except for inventions, trade secrets or proprietary
information that have been rightfully assigned to the Company. 
  
 4.11 Compliance with Other Instruments. Except as disclosed in any Exchange Act Filings, the Company is not in violation or default of (x) any term of its Charter or Bylaws, or (y) of any provision of any indebtedness, mortgage,
indenture, contract, agreement or instrument to which it is party or by which it is bound or of any judgment, decree, order or writ, which violation or default, in the case of this clause (y), has had, or could reasonably be expected to have, either
individually or in the aggregate, a Material Adverse Effect. The execution, delivery and performance of and compliance with this Agreement and the Related Agreements to which it is a party, and the issuance and sale of the Note by the Company and
the other Securities by the Company each pursuant hereto and thereto, will not, with or without the passage of time or giving of notice, result in any such material violation, or be in conflict with or constitute a default under any such term or
provision, or result in the creation of any mortgage, pledge, lien, encumbrance or charge upon any of the properties or assets of the Company or the suspension, revocation, impairment, forfeiture or nonrenewal of any permit, license, authorization
or approval applicable to the Company, its business or operations or any of its assets or properties. 
  
 4.12 Litigation. Except as set forth on Schedule 4.12 hereto or as disclosed in any Exchange Act Filings, there is no action, suit, proceeding or
investigation pending or, to the Company’s knowledge, currently threatened against the Company that prevents the Company from entering into this Agreement or the Related Agreements, or from consummating the transactions contemplated hereby or
thereby, or which has had, or could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect or could result in any 
  

 8 








 change in the current equity ownership of the Company, nor is the Company aware that there is any basis to assert any of
the foregoing. The Company is not a party or subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality. There is no action, suit, proceeding or investigation by the Company
currently pending or which the Company intends to initiate. 
  
 4.13 Tax Returns and Payments. The Company has timely filed all tax returns (federal, state and local) required to be filed by it. All taxes shown to be due and payable on such returns, any assessments imposed, and all other taxes
due and payable by the Company on or before the Closing, have been paid or will be paid prior to the time they become delinquent. Except as set forth on Schedule 4.13 or as disclosed in any Exchange Act Filings, the Company has not been advised:

  
 (a) that any of its returns, federal, state
or other, have been or are being audited as of the date hereof; or 
  
 (b) of any deficiency in assessment or proposed judgment to its federal, state or other taxes. 
  
 The Company has no knowledge of any liability of any tax to be imposed upon its properties or assets as of the date of this Agreement that is not adequately provided for.

  
 4.14 Employees. Except as set forth on Schedule 4.14 or
as disclosed in any Exchange Act Filings, the Company has no collective bargaining agreements with any of its employees. There is no labor union organizing activity pending or, to the Company’s knowledge, threatened with respect to the Company.
Except as disclosed in the Exchange Act Filings or on Schedule 4.14, the Company is not a party to or bound by any currently effective employment contract, deferred compensation arrangement, bonus plan, incentive plan, profit sharing plan,
retirement agreement or other employee compensation plan or agreement. To the Company’s knowledge, no employee of the Company, nor any consultant with whom the Company has contracted, is in violation of any term of any employment contract,
proprietary information agreement or any other agreement relating to the right of any such individual to be employed by, or to contract with, the Company because of the nature of the business to be conducted by the Company; and to the Company’s
knowledge the continued employment by the Company of its present employees, and the performance of the Company’s contracts with its independent contractors, will not result in any such violation. The Company is not aware that any of its
employees is obligated under any contract (including licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would interfere with their duties to
the Company. The Company has not received any notice alleging that any such violation has occurred. Except for employees who have a current effective employment agreement with the Company, no employee of the Company has been granted the right to
continued employment by the Company or to any material compensation following termination of employment with the Company. Except as set forth on Schedule 4.14 or as disclosed in any Exchange Act Filings, the Company is not aware that any officer,
key employee or group of employees intends to terminate his, her or their employment with the Company, nor does the Company have a present intention to terminate the employment of any officer, key employee or group of employees. 
  

 9 








 4.15 Registration Rights and Voting Rights. Except as set forth on Schedule 4.15 and except as
disclosed in Exchange Act Filings, the Company is presently not under any obligation, and has not granted any rights, to register any of the Company’s presently outstanding securities or any of its securities that may hereafter be issued.
Except as set forth on Schedule 4.15 and except as disclosed in Exchange Act Filings, to the Company’s knowledge, no stockholder of the Company has entered into any agreement with respect to the voting of equity securities of the Company.

  
 4.16 Compliance with Laws; Permits. The Company is not
in violation of any applicable statute, rule, regulation, order or restriction of any domestic or foreign government or any instrumentality or agency thereof in respect of the conduct of its business or the ownership of its properties which has had,
or could reasonably be expected to have, either individually or in the aggregate, a Material Adverse Effect. No governmental orders, permissions, consents, approvals or authorizations are required to be obtained and no registrations or declarations
are required to be filed in connection with the execution and delivery of this Agreement or any Related Agreement and the issuance of any of the Securities, except such as has been duly and validly obtained or filed, or with respect to any filings
that must be made after the Closing, as will be filed in a timely manner. The Company has all material franchises, permits, licenses and any similar authority necessary for the conduct of its business as now being conducted by it, the lack of which
could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 
  
 4.17 Environmental and Safety Laws. The Company is not in violation of any applicable statute, law or regulation relating to the environment or
occupational health and safety, and to its knowledge, no material expenditures are or will be required in order to comply with any such existing statute, law or regulation. Except as set forth on Schedule 4.17 or as disclosed in any Exchange Act
Filings, no Hazardous Materials (as defined below) are used or have been used, stored, or disposed of by the Company or, to the Company’s knowledge, by any other person or entity on any property owned, leased or used by the Company. For the
purposes of the preceding sentence, “Hazardous Materials” shall mean: 
  
 (a) materials which are listed or otherwise defined as “hazardous” or “toxic” under any applicable local, state,
federal and/or foreign laws and regulations that govern the existence and/or remedy of contamination on property, the protection of the environment from contamination, the control of hazardous wastes, or other activities involving hazardous
substances, including building materials; or 
  
 (b) any petroleum products or nuclear materials. 
  
 4.18
Valid Offering. Assuming the accuracy of the representations and warranties of the Purchaser contained in this Agreement, the Company will take all steps necessary to secure an exemption from the registration requirements of the Securities
Act of 1933, as amended (the “Securities Act”), for the offer and sale of the Securities and will take the steps to register or qualify (or secure an exemption from registration and qualification) under the registration, permit or
qualification requirements of all applicable state securities laws. 
  

 10 








 4.19 Full Disclosure. The Company has provided, furnished or provided access to the Purchaser
regarding all information requested by the Purchaser in connection with its decision to purchase the Note and Warrant, including all information the Company believes is reasonably necessary to make such investment decision. Neither this Agreement,
the Related Agreements, nor the exhibits and schedules hereto and thereto, when incorporated with the Exchange Act Filings, nor any other document delivered by the Company to Purchaser or its attorneys or agents in connection herewith or therewith
or with the transactions contemplated hereby or thereby, contain any untrue statement of a material fact nor omit to state a material fact necessary in order to make the statements contained herein or therein, in light of the circumstances in which
they are made, not misleading. Any financial projections and other estimates provided to the Purchaser by the Company were based on the Company’s experience in the industry and on assumptions of fact and opinion as to future events which the
Company, at the date of the issuance of such projections or estimates, believed to be reasonable. 
  
 4.20 Insurance. The Company has general commercial, product liability, fire and casualty insurance policies with coverages which the Company
believes are customary for companies similarly situated to the Company in the same or similar business. 
  
 4.21 SEC Reports. Except as set forth on Schedule 4.21 or in the Exchange Act Filings, the Company has filed all proxy statements, reports and
other documents required to be filed by it under the Securities Exchange Act 1934, as amended (the “Exchange Act”). The Company has furnished the Purchaser with copies of: (i) its Annual Report on Form 10-K for the fiscal year ended
December 31, 2003; and (ii) its Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2004 and June 30, 2004 and the Form 8-K filings which it has made during the fiscal year 2004 to date (collectively, the “SEC Reports”).
Except as set forth on Schedule 4.21, each SEC Report was, at the time of its filing, in substantial compliance with the requirements of its respective form and none of the SEC Reports, nor the financial statements (and the notes thereto) included
in the SEC Reports, as of their respective filing dates, contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading. 
  
 4.22
Listing. The Company’s Common Stock is listed for trading on the Nasdaq National Market (“Nasdaq National”) and satisfies all requirements for the continuation of such listing, except as disclosed in any Exchange Act Filings.

  
 4.23 No Integrated Offering. Neither the Company, nor
any of its affiliates, nor any person acting on its or their behalf, has directly or indirectly made any offers or sales of any security or solicited any offers to buy any security under circumstances that would cause the offering of the Securities
pursuant to this Agreement or any Related Agreement to be integrated with prior offerings by the Company for purposes of the Securities Act which would prevent the Company from selling the Securities pursuant to Rule 506 under the Securities Act, or
any applicable exchange-related stockholder approval provisions, nor will the Company or any of its affiliates or subsidiaries take any action or steps that would cause the offering of the Securities to be integrated with other offerings.

  

 11 








 4.24 Stop Transfer. The Securities are restricted securities as of the date of this Agreement. The
Company will not issue any stop transfer order or other order impeding the sale and delivery of any of the Securities at such time as the Securities are registered for public sale or an exemption from registration is available, except if any
material misrepresentation has occurred in connection with the Purchaser’s representations and warranties in connection with their investment in the Securities or as required by the National Association of Securities Dealers, state and federal
securities laws. 
  
 4.25 Dilution. Except as set forth in
paragraph 4.24, the Company specifically acknowledges that its obligation to issue the shares of Common Stock upon conversion of the Note and exercise of the Warrant is binding upon the Company and enforceable regardless of the dilution such
issuance may have on the ownership interests of other shareholders of the Company. 
  
 4.26 Patriot Act. The Company certifies that, to the best of Company’s knowledge, the Company has not been designated, and is not owned or controlled, by a “suspected terrorist” as defined in
Executive Order 13224. The Company hereby acknowledges that the Purchaser seeks to comply with all applicable laws concerning money laundering and related activities. In furtherance of those efforts, the Company hereby represents, warrants and
agrees that: (i) none of the cash or property that the Company will pay or will contribute to the Purchaser has been or shall be derived from, or related to, any activity that is deemed criminal under United States law; and (ii) no contribution or
payment by the Company to the Purchaser, to the extent that they are within the Company’s control shall cause the Purchaser to be in violation of the United States Bank Secrecy Act, the United States International Money Laundering Control Act
of 1986 or the United States International Money Laundering Abatement and Anti-Terrorist Financing Act of 2001. The Company shall promptly notify the Purchaser if any of these representations ceases to be true and accurate regarding the Company. The
Company agrees to provide the Purchaser any additional information regarding the Company that the Purchaser deems necessary or convenient to ensure compliance with all applicable laws concerning money laundering and similar activities. The Company
understands and agrees that if at any time it is discovered that any of the foregoing representations are incorrect, or if otherwise required by applicable law or regulation related to money laundering similar activities, the Purchaser may undertake
appropriate actions to ensure compliance with applicable law or regulation, including but not limited to segregation and/or redemption of the Purchaser’s investment in the Company. The Company further understands that the Purchaser may release
confidential information about the Company and, if applicable, any underlying beneficial owners, to proper authorities if the Purchaser, in its sole discretion, determines that it is in the best interests of the Purchaser in light of relevant rules
and regulations under the laws set forth in subsection (ii) above. 
  
 5.
Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Company as follows (such representations and warranties do not lessen or obviate the representations and warranties of the Company set forth
in this Agreement) 
  
 5.1 No Shorting. The Purchaser or
any of its affiliates and investment partners have not in the past or present, and will not in the future by themselves or cause any person or entity, to directly engage in “short sales” of the Company’s Common Stock as long as the
Note shall be outstanding. 
  

 12 








 5.2 Requisite Power and Authority. The Purchaser has all necessary power and authority under all
applicable provisions of law to execute and deliver this Agreement and the Related Agreements and to carry out their provisions. All corporate action on Purchaser’s part required for the lawful execution and delivery of this Agreement and the
Related Agreements have been or will be effectively taken prior to the Closing. Upon their execution and delivery, this Agreement and the Related Agreements will be valid and binding obligations of Purchaser, enforceable in accordance with their
terms, except: 
  
 (a) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights; and 
  
 (b) as limited by general principles of equity that restrict the availability of equitable and legal remedies. 
  
 5.3 Investment Representations. Purchaser understands that the
Securities are being offered and sold pursuant to an exemption from registration contained in the Securities Act based in part upon Purchaser’s representations contained in the Agreement, including, without limitation, that the Purchaser is an
“accredited investor” within the meaning of Regulation D under the Securities Act of 1933, as amended (the “Securities Act”). The Purchaser confirms that it has received or has had full access to all the information it considers
necessary or appropriate to make an informed investment decision with respect to the Note and the Warrant to be purchased by it under this Agreement and the Note Shares and the Warrant Shares acquired by it upon the conversion of the Note and the
exercise of the Warrant, respectively. The Purchaser further confirms that it has had an opportunity to ask questions and receive answers from the Company regarding the Company’s business, management and financial affairs and the terms and
conditions of the Offering, the Note, the Warrant and the Securities and to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any
information furnished to the Purchaser or to which the Purchaser had access. Purchaser further warrants that it is purchasing the securities in accordance with all of the requirements set forth under Regulation D of the Securities Act and the Rules
promulgated thereunder. Purchaser will cooperate with the Company in supplying any information requested by the Company pursuant to any filing required to secure an exemption from registration at either state or federal law. 
  
 5.4 Purchaser Bears Economic Risk. The Purchaser has substantial
experience in evaluating and investing in private placement transactions of securities in companies similar to the Company so that it is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its
own interests. The Purchaser must bear the economic risk of this investment until the Securities are sold pursuant to: (i) an effective registration statement under the Securities Act; or (ii) an exemption from registration is available with respect
to such sale. 
  

 13 








 5.5 Acquisition for Own Account. The Purchaser is acquiring the Note and Warrant and the Note
Shares and the Warrant Shares for the Purchaser’s own account for investment only, and not as a nominee or agent and not with a view towards or for resale in connection with their distribution. 
  
 5.6 Purchaser Can Protect Its Interest. The Purchaser represents that
by reason of its, or of its management’s, business and financial experience, the Purchaser has the capacity to evaluate the merits and risks of its investment in the Note, the Warrant and the Securities and to protect its own interests in
connection with the transactions contemplated in this Agreement, and the Related Agreements. Further, the Purchaser is aware of no publication of any advertisement in connection with the transactions contemplated in the Agreement or the Related
Agreements. 
  
 5.7 Accredited Investor. Purchaser
represents that it is an accredited investor within the meaning of Regulation D under the Securities Act. 
  
 5.8 Legends. 
  
 (a) The Note shall bear substantially the following legend: 
  
 “THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT
OF 1933, AS AMENDED, OR ANY APPLICABLE, STATE SECURITIES LAWS. THIS NOTE AND THE COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS
TO THIS NOTE OR SUCH SHARES UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO ICORIA, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.” 
  
 (b) The Note Shares and the Warrant Shares, if not issued by
DWAC system (as hereinafter defined), shall bear a legend which shall be in substantially the following form until such shares are covered by an effective registration statement filed with the SEC: 
  
 “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE, STATE SECURITIES LAWS. THESE SHARES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH SECURITIES ACT AND
APPLICABLE STATE LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO ICORIA, INC. THAT SUCH REGISTRATION IS NOT REQUIRED.” 
  

 14 








 (c) The Warrant shall bear substantially the following legend: 
  
 “THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS
WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT AND THE COMMON SHARES ISSUABLE UPON EXERCISE OF THIS WARRANT MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR
HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THIS WARRANT OR THE UNDERLYING SHARES OF COMMON STOCK UNDER SAID ACT AND APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO ICORIA, INC. THAT
SUCH REGISTRATION IS NOT REQUIRED.” 
  
 6. Covenants of the Company.
The Company covenants and agrees with the Purchaser as follows: 
  
 6.1 Stop-Orders. The Company will advise the Purchaser, promptly after it receives notice of issuance by the Securities and Exchange Commission (the “SEC”), any state securities commission or any other regulatory authority
of any stop order or of any order preventing or suspending any offering of any securities of the Company, or of the suspension of the qualification of the Common Stock of the Company for offering or sale in any jurisdiction, or the initiation of any
proceeding for any such purpose. 
  
 6.2 Listing. The
Company shall promptly secure the listing of the shares of Common Stock issuable upon conversion of the Note and upon the exercise of the Warrant on the Nasdaq National Market, the Nasdaq Small Cap, or the Over the Counter Bulletin Board (the
“Principal Market”) (subject to official notice of issuance) and shall maintain such status so long as any other shares of Common Stock shall be so quoted on such Principal Market. It is expressly understood that movement between any
exchange or quotation service set forth herein is permissible and shall not be a breach of this or any other covenant contained herein or in the Related Agreements. The Company will maintain the quotation of its Common Stock on the Principal Market,
and will comply in all material respects with the Company’s reporting, filing and other obligations under the bylaws or rules of the National Association of Securities Dealers (“NASD”), such exchanges or quotation services, as
applicable. 
  
 6.3 Market Regulations. The Company shall
notify the SEC, NASD and applicable state authorities, in accordance with their requirements, of the transactions contemplated by this Agreement, and shall take all other necessary action and proceedings as may be required and permitted by
applicable law, rule and regulation, for the legal and valid issuance of the Securities to the Purchaser and promptly provide copies thereof to the Purchaser. 
  

6.4 Reporting Requirements. The Company will use all commercially reasonable efforts to timely file with the SEC all reports required to be
filed pursuant to the Exchange Act and refrain from terminating its status as an issuer required by the Exchange Act to file reports thereunder even if the Exchange Act or the rules or regulations thereunder would permit such termination.

  

 15 








 6.5 Use of Funds-Guideline. The Company agrees that the proceeds of (x) the sale of the Note shall
be generally utilized pursuant to the following guideline. The funds will be used: (i) to repay in full all existing indebtedness owed by the Company to GE Capital, pursuant to the Master Security Agreement No. 7237 and to terminate such credit
facility, (ii) generally for capital expenditures to be made by the Company and its Subsidiaries (subject to fluctuation in market prices) in an aggregate amount of $1,600,000, (iii) generally for the purchase of chemical libraries and outsourced
studies (subject to fluctuation in market prices) in an aggregate amount of $1,200,000, (iv) for expenses incurred in connection with the transactions contemplated by this Agreement and the Related Agreements and (v) for general working capital
purposes of the Company and its Subsidiaries and (y) the sale of the Warrant shall be utilized for general working capital purposes. 
  
 6.6 Access to Facilities. The Company will permit any representatives designated by the Purchaser (or any successor of the Purchaser), upon
reasonable notice and during normal business hours, at such person’s expense, while covered by Purchaser’s or their successor’s own insurance for such an on-site investigation and accompanied by a representative of the Company, to:

  
 (a) visit and inspect any of the properties
of the Company; 
  
 (b) examine the corporate and
financial records of the Company (unless such examination is not permitted by federal, state or local law or by contract) and make copies thereof or extracts therefrom; and 
  
 (c) discuss the affairs, finances and accounts of the Company with the directors, officers and independent
accountants of the Company . 
  
 Notwithstanding the foregoing, the Company will
not provide any material, non-public information to the Purchaser (or any successor of the Purchaser) unless the Purchaser (or any successor of the Purchaser) signs a confidentiality agreement and otherwise complies with Regulation FD, under the
federal securities laws. 
  
 6.7 Taxes. The Company will
promptly pay and discharge, or cause to be paid and discharged, when due and payable, all lawful taxes, assessments and governmental charges or levies imposed upon the income, profits, property or business of the Company; provided, however, that any
such tax, assessment, charge or levy need not be paid if the validity thereof shall currently be contested in good faith by appropriate proceedings and if the Company shall have set aside on its books adequate reserves with respect thereto, and
provided, further, that the Company will pay all such taxes, assessments, charges or levies forthwith upon the commencement of proceedings to foreclose any lien which may have attached as security therefor. 
  
 6.8 Insurance. The Company will keep its assets which are of an
insurable character insured by financially sound and reputable insurers against loss or damage by fire, explosion and other risks customarily insured against by companies in similar business similarly 
  

 16 








 situated as the Company; and the Company will maintain, with financially sound and reputable insurers, insurance against
other hazards and risks and liability to persons and property to the extent and in the manner which the Company reasonably believes is customary for companies in similar business similarly situated as the Company and to the extent available on
commercially reasonable terms. The Company and each of its Subsidiaries will jointly and severally bear the full risk of loss from any loss of any nature whatsoever with respect to the assets pledged to the Purchaser as security for its obligations
hereunder and under the Related Agreements. At the Company’s own cost and expense in amounts and with carriers reasonably acceptable to Purchaser, the Company and each of the Subsidiaries shall (i) keep all its insurable properties and
properties in which it has an interest insured against the hazards of fire, flood, sprinkler leakage, those hazards covered by extended coverage insurance and such other hazards, and for such amounts, as is customary in the case of companies engaged
in businesses similar to the Company’s or the respective Subsidiary’s including business interruption insurance; (ii) maintain insurance against claims for personal injury, death or property damage suffered by others in such amounts as is
customary in the industry in which the Company operates its business; (iii) Intentionally Deleted; (iv) maintain all such worker’s compensation or similar insurance as may be required under the laws of any state or jurisdiction in which the
Company or the Subsidiary is engaged in business; and (v) furnish Purchaser with (x) evidence of the maintenance of such policies at least thirty (30) days before any expiration date, (y) excepting the Company’s workers’ compensation
policy, endorsements to such policies naming Purchaser as “co-insured” or “additional insured” and appropriate loss payable endorsements in form and substance satisfactory to Purchaser, naming Purchaser as loss payee, and (z)
evidence that as to Purchaser the insurance coverage shall not be impaired or invalidated by any act or neglect of the Company or any Subsidiary and the insurer will provide Purchaser with at least thirty (30) days notice prior to cancellation. The
Company and each Subsidiary shall instruct the insurance carriers that in the event of any loss thereunder, the carriers shall make payment for such loss to the Company and/or the Subsidiary and Purchaser jointly. In the event that as of the date of
receipt of each loss recovery upon any such insurance, the Purchaser has not declared an event of default with respect to this Agreement or any of the Related Agreements, then the Company shall be permitted to direct the application of such loss
recovery proceeds toward investment in property, plant and equipment that would comprise “Collateral” secured by Purchaser’s security interest pursuant to its security agreement, with any surplus funds to be applied toward payment of
the obligations of the Company to Purchaser. In the event that Purchaser has properly declared an event of default with respect to this Agreement or any of the Related Agreements, then all loss recoveries received by Purchaser upon any such
insurance thereafter may be applied to the obligations of the Company hereunder and under the Related Agreements, in such order as the Purchaser may determine. Any surplus (following satisfaction of all Company obligations to Purchaser) shall be
paid by Purchaser to the Company or applied as may be otherwise required by law. Any deficiency thereon shall be paid by the Company or the Subsidiary, as applicable, to Purchaser, on demand. 
  
 6.9 Intellectual Property. The Company shall maintain in full force
and effect its corporate existence, rights and franchises and all licenses and other rights to use Intellectual Property owned or possessed by it and reasonably deemed to be necessary to the conduct of its business. 
  

 17 








 6.10 Properties. The Company will keep its properties in good repair, working order and condition,
reasonable wear and tear excepted, and from time to time make all needful and proper repairs, renewals, replacements, additions and improvements thereto; and the Company will at all times comply with each provision of all leases to which it is a
party or under which it occupies property if the breach of such provision could reasonably be expected to have a Material Adverse Effect. 
  
 6.11 Confidentiality. The Company agrees that it will not disclose, and will not include in any public announcement, the name of the Purchaser,
unless expressly agreed to by the Purchaser or unless and until such disclosure is required by law or applicable regulation, and then only to the extent of such requirement. The Company may disclose Purchaser’s identity and the terms of this
Agreement to its current and prospective debt and equity financing sources and as required by law or applicable regulation. 
  
 6.12 Required Approvals. For so long as twenty -five percent (25%) of the principal amount of the Note is outstanding, the Company, without the
prior written consent of the Purchaser, which shall not be unreasonably withheld, shall not: 
  
 (a) (i) directly or indirectly declare or pay any dividends, other than dividends paid to the Parent or any of its wholly-owned
Subsidiaries, (ii) issue any preferred stock that is mandatorily redeemable prior to October 19, 2007, or (iii) redeem any of its preferred stock or other equity interests during before the Maturity Date ; 
  
 (b) liquidate, dissolve or effect a material reorganization
(it being understood that in no event shall the Company dissolve, liquidate or merge with any other person or entity unless, the Company is the surviving entity or the successor entity expressly assumes all of the duties and obligations of the
Company and its Subsidiaries under this Agreement and Related Agreements); 
  
 (c) become subject to (including, without limitation, by way of amendment to or modification of) any agreement or instrument which by its terms would (under any circumstances) materially restrict the Company’s
right to perform the provisions of this Agreement or any of the agreements contemplated thereby; 
  
 (d) materially alter or change the scope of business of the Company, unless such change in scope is consistent with past practice;

  
 (e) (i) create, incur, assume or suffer to
exist any indebtedness, exclusive of trade debt, debt subordinated to or on collateral other than the security provided by the Related Agreements and debt incurred to finance the purchase of equipment (not in excess of ten percent (10%) of the fair
market value of the Company’s and its Subsidiaries’ assets) whether secured or unsecured other than (x) the Company’s indebtedness to the Purchaser, (y) indebtedness set forth on Schedule 6.12(e) attached hereto and made a part
hereof and any refinancings or replacements thereof on terms no less favorable to the Purchaser than the debt being refinanced or replaced, and (z) any indebtedness incurred in connection with the purchase of assets in the ordinary course of
business, and any refinancings or replacements thereof on terms no less favorable to the 
  

 18 








 Purchaser than the indebtedness being refinanced or replaced; (ii) cancel any indebtedness owing to it in
excess of $200,000 in the aggregate during any 12 month period; (iii) assume, guarantee, endorse or otherwise become directly or contingently liable in connection with any obligations of any other Person, except the endorsement of negotiable
instruments by the Company for deposit or collection or similar transactions in the ordinary course of business; and 
  
 (f) (i) make investments in, make any loans or advances to, or transfer assets to, any of its Subsidiaries, other than any immaterial
investments, loans, advances and/or asset transfers made in the ordinary course of business or (ii) create or acquire any Subsidiary without the prior written consent of the Purchaser, which shall not be unreasonably withheld. 
  
 6.13 Reissuance of Securities. The Company agrees to reissue
certificates representing the Securities without the legends set forth in Section 5.8 above at such time as: 
  
 (a) the holder thereof is permitted to dispose of such Securities pursuant to Rule 144(k) under the Securities Act; or 
  
 (b) upon resale subject to an effective registration
statement after such Securities are registered under the Securities Act. 
  
 The
Company agrees to cooperate with the Purchaser in connection with all resales pursuant to Rule 144(d) and Rule 144(k) and provide legal opinions necessary to allow such resales provided the Company and its counsel receive reasonably requested
representations from the selling Purchaser and broker, if any. 
  
 6.14 Opinion. On the Closing Date, the Company will deliver to the Purchaser an opinion acceptable to the Purchaser from the Company’s legal counsel. The Company will provide, at the Company’s expense, such other legal
opinions in the future as are reasonably necessary for the conversion of the Note and exercise of the Warrant. 
  
 6.15 Margin Stock. The Company will not permit any of the proceeds of the Note or the Warrant to be used directly or indirectly to
“purchase” or “carry” “margin stock” or to repay indebtedness incurred to “purchase” or “carry” “margin stock” within the respective meanings of each of the quoted terms under Regulation U
of the Board of Governors of the Federal Reserve System as now and from time to time hereafter in effect. 
  
 6.16 The Company will not, and will not permit its Subsidiaries to, agree, directly or indirectly, to any restriction with any person or entity which
limits the ability of the Purchaser to consummate an additional financing with the Company or any of its Subsidiaries. 
  
 7. Covenants of the Purchaser. The Purchaser covenants and agrees with the Company as follows: 
  
 7.1 Confidentiality. The Purchaser agrees that it will not disclose, and will not include in any public announcement,
the name of the Company, unless expressly agreed to by the Company or unless and until such disclosure is required by law or applicable regulation, and then only to the extent of such requirement. 
  

 19 








 7.2 Non-Public Information. The Purchaser agrees not to effect any sales in the shares of the
Company’s Common Stock while in possession of material, non-public information regarding the Company if such sales would violate applicable securities law. 
  

8. Covenants of the Company and Purchaser Regarding Indemnification. 
  

8.1 Company Indemnification. The Company agrees to indemnify, hold harmless, reimburse and defend Purchaser, each of Purchaser’s officers,
directors, agents, affiliates, control persons, and principal shareholders, against any forseeable: claim, cost, expense, liability, obligation, loss or damage (including reasonable legal fees) of any nature, incurred by or imposed upon the
Purchaser which results, arises out of or is based upon: (i) any misrepresentation by Company or breach of any warranty by Company in this Agreement, any Related Agreement or in any exhibits or schedules attached hereto or thereto; or (ii) any
breach or default in performance by Company of any covenant or undertaking to be performed by Company hereunder, or any other agreement entered into by the Company and Purchaser relating hereto. 
  
 8.2 Purchaser’s Indemnification. Purchaser agrees to indemnify,
hold harmless, reimburse and defend the Company and each of the Company’s officers, directors, agents, affiliates, control persons and principal shareholders, at all times against any claim, cost, expense, liability, obligation, loss or damage
(including reasonable legal fees) of any nature, incurred by or imposed upon the Company which results, arises out of or is based upon: (i) any misrepresentation by Purchaser or breach of any warranty by Purchaser in this Agreement or in any
exhibits or schedules attached hereto or any Related Agreement; or (ii) any breach or default in performance by Purchaser of any covenant or undertaking to be performed by Purchaser hereunder, or any other agreement entered into by the Company and
Purchaser relating hereto. 
  
 9. Conversion of Convertible Note.

  
 9.1 Mechanics of Conversion. 
  
 (a) Provided the Purchaser has notified the Company of the
Purchaser’s intention to sell the Note Shares and the Note Shares are included in an effective registration statement or are otherwise exempt from registration when sold: (i) Upon the conversion of the Note or part thereof, the Company shall,
at its own cost and expense, take all necessary action (including the issuance of an opinion of counsel reasonably acceptable to the Purchaser following a request by the Purchaser) to assure that the Company’s transfer agent shall issue shares
of the Company’s Common Stock in the name of the Purchaser (or its nominee) or such other persons as designated by the Purchaser in accordance with Section 9.1(b) hereof and in such denominations to be specified representing the number of Note
Shares issuable upon such conversion; and (ii) The Company warrants that no instructions other than these instructions have been or will be given to the transfer agent of the Company’s Common Stock and that after the Effectiveness Date (as
defined in the Registration Rights Agreement) the Note Shares 
  

 20 








 issued will be freely transferable subject to the prospectus delivery requirements of the Securities Act
and the provisions of this Agreement, and will not contain a legend restricting the resale or transferability of the Note Shares. 
  
 (b) Purchaser will give notice of its decision to exercise its right to convert the Note or part thereof by telecopying or otherwise
delivering an executed and completed notice of the number of shares to be converted to the Company (the “Notice of Conversion”). The Purchaser will surrender the Note previous to the Purchaser receiving a credit to the account of the
Purchaser’s prime broker through the DWAC system (as defined below), representing the Note Shares or until the Note has been fully satisfied. Each date on which a Notice of Conversion is telecopied or delivered to the Company in accordance with
the provisions hereof shall be deemed a “Conversion Date.” Pursuant to the terms of the Notice of Conversion, the Company will issue instructions to the transfer agent accompanied by an opinion of counsel within three (3) business days of
the date of the delivery to the Company of the Notice of Conversion and shall cause the transfer agent to transmit the certificates representing the Conversion Shares to the Holder by crediting the account of the Purchaser’s prime broker with
the Depository Trust Company (“DTC”) through its Deposit Withdrawal Agent Commission (“DWAC”) system within three (3) business days after the creation and delivery of the opinion of counsel to the transfer agent pursuant to the
Company’s Notice of Conversion (the “Delivery Date”). 
  
 (c) The Company understands that a delay in the delivery of the Note Shares in the form required pursuant to Section 9 hereof beyond the Delivery Date could result in economic loss to the Purchaser. In the event that
the Company fails to direct its transfer agent to deliver the Note Shares to the Purchaser via the DWAC system within the time frame set forth in Section 9.1(b) above and the Note Shares are not delivered to the Purchaser by the Delivery Date, and
is not cured within two (2) business days after the Delivery Date, as compensation to the Purchaser for such loss, the Company agrees to pay late payments to the Purchaser for late issuance of the Note Shares in the form required pursuant to Section
9 hereof upon conversion of the Note in the amount equal to the greater of: (i) $500 per business day after the Delivery Date, including the period for cure. Notwithstanding the foregoing, the Company will not owe the Purchaser any late payments if
the delay in the delivery of the Note Shares beyond the Delivery Date is solely out of the control of the Company and the Company is actively trying to cure the cause of the delay, or the Company cures within the two (2) business days following the
Delivery Date. The Company shall pay any payments incurred under this Section in immediately available funds upon demand. 
  
 Nothing contained herein or in any document referred to herein or delivered in connection herewith shall be deemed to establish or require the payment of a rate of
interest or other charges in excess of the maximum permitted by applicable law. In the event that the rate of interest or dividends required to be paid or other charges hereunder exceed the maximum amount permitted by such law, any payments in
excess of such maximum shall be credited against amounts owed by the Company to a Purchaser and thus refunded to the Company. 
  

 21 








 10. Registration Rights. 
  

10.1 Registration Rights Granted. The Company hereby grants registration rights to the Purchaser pursuant to a Registration Rights Agreement
dated as of even date herewith between the Company and the Purchaser. 
  
 10.2 Offering Restrictions. Except as previously disclosed in the Exchange Act Filings, or stock or stock options granted to employees or directors of the Company (these exceptions hereinafter referred to as the “Excepted
Issuances”), the Company will not issue any securities with a continuously variable/floating conversion feature which are or could be (by conversion or registration) free-trading securities (i.e. common stock subject to a registration
statement) prior to the full repayment or conversion of the Note (together with all accrued and unpaid interest and fees related thereto. 
  
 11. Miscellaneous. 
  
 11.1 Governing Law. THIS AGREEMENT AND EACH RELATED AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW
YORK, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS. ANY ACTION BROUGHT BY EITHER PARTY AGAINST THE OTHER CONCERNING THE TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT AND EACH RELATED AGREEMENT SHALL BE BROUGHT ONLY IN THE STATE COURTS OF NEW YORK
OR IN THE FEDERAL COURTS LOCATED IN THE STATE OF NEW YORK. BOTH PARTIES AND THE INDIVIDUALS EXECUTING THIS AGREEMENT AND THE RELATED AGREEMENTS ON BEHALF OF THE COMPANY AGREE TO SUBMIT TO THE JURISDICTION OF SUCH COURTS AND WAIVE TRIAL BY JURY. IN
THE EVENT THAT ANY PROVISION OF THIS AGREEMENT OR ANY RELATED AGREEMENT DELIVERED IN CONNECTION HEREWITH IS INVALID OR UNENFORCEABLE UNDER ANY APPLICABLE STATUTE OR RULE OF LAW, THEN SUCH PROVISION SHALL BE DEEMED INOPERATIVE TO THE EXTENT THAT IT
MAY CONFLICT THEREWITH AND SHALL BE DEEMED MODIFIED TO CONFORM WITH SUCH STATUTE OR RULE OF LAW. ANY SUCH PROVISION WHICH MAY PROVE INVALID OR UNENFORCEABLE UNDER ANY LAW SHALL NOT AFFECT THE VALIDITY OR ENFORCEABILITY OF ANY OTHER PROVISION OF THIS
AGREEMENT OR ANY RELATED AGREEMENT. 
  
 11.2 Survival. The
representations, warranties, covenants and agreements made herein shall survive any investigation made by the Purchaser and the closing of the transactions contemplated hereby to the extent provided therein. All statements as to factual matters
contained in any certificate or other instrument delivered by or on behalf of the Company pursuant hereto in connection with the transactions contemplated hereby shall be deemed to be representations and warranties by the Company hereunder solely as
of the date of such certificate or instrument. 
  
 11.3
Successors. Except as otherwise expressly provided herein, the provisions hereof shall inure to the benefit of, and be binding upon, the successors, heirs, executors and administrators of the parties hereto and shall inure to the benefit of
and be enforceable by each person who shall be a holder of the Securities from time to time, other than the holders of Common Stock which has been sold by the Purchaser pursuant to Rule 144 or an effective registration statement. Purchaser may not
assign its rights hereunder to a competitor of the Company. 
  

 22 








 11.4 Entire Agreement. This Agreement, the Related Agreements, the exhibits and schedules hereto
and thereto and the other documents delivered pursuant hereto constitute the full and entire understanding and agreement between the parties with regard to the subjects hereof and no party shall be liable or bound to any other in any manner by any
representations, warranties, covenants and agreements except as specifically set forth herein and therein. 
  
 11.5 Severability. In case any provision of the Agreement shall be invalid, illegal or unenforceable, the validity, legality and enforceability of
the remaining provisions shall not in any way be affected or impaired thereby. 
  
 11.6 Amendment and Waiver. 
  
 (a) This Agreement may be amended or modified only upon the written consent of the Company and the Purchaser. 
  
 (b) The obligations of the Company and the rights of the Purchaser under this Agreement may be waived only with the written consent of the
Purchaser. 
  
 (c) The obligations of the
Purchaser and the rights of the Company under this Agreement may be waived only with the written consent of the Company. 
  
 11.7 Delays or Omissions. It is agreed that no delay or omission to exercise any right, power or remedy accruing to any party, upon any breach,
default or noncompliance by another party under this Agreement or the Related Agreements, shall impair any such right, power or remedy, nor shall it be construed to be a waiver of any such breach, default or noncompliance, or any acquiescence
therein, or of or in any similar breach, default or noncompliance thereafter occurring. All remedies, either under this Agreement, or the Related Agreements, by law or otherwise afforded to any party, shall be cumulative and not alternative.

  
 11.8 Notices. All notices required or permitted
hereunder (other than as expressly set forth herein) shall be in writing and shall be deemed effectively given: 
  
 (a) upon personal delivery to the party to be notified; 
  
 (b) when sent by confirmed facsimile if sent during normal business hours of the recipient, if not, then on
the next business day; 
  
 (c) five (5) business
days after having been sent by registered or certified mail, return receipt requested, postage prepaid; or 
  
 (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of
receipt. 
  

 23 








 All communications shall be sent as follows: 
  

					
	If to the Company, to:	  	 Icoria, Inc.
 108 T.W. Alexander Drive,
Research Triangle Park,
 North Carolina 27709

			
	 	  	Attention:	    	 
			
	 	  	 	    	 Barry Buzogany
 General Counsel

			
	 	  	Telephone:	    	(919) 425-3000
			
	 	  	Facsimile:	    	919-425-2915
		
	 	  	with a copy to: Neil Aronson, Esq.
	 	  	Mintz Levin Cohn Ferris Glovsky & Popeo PC
	 	  	 Telephone (617)-542-6000
 Facsimile:
617-542-2241

		
	If to the Purchaser, to:	  	 Laurus Master Fund, Ltd.
 M&C
Corporate Services Limited
 P.O. Box 309 GT
 Ugland
House
 George Town
 South Church Street
 Grand Cayman, Cayman Islands

	 	  	Facsimile:	    	345-949-8080
		
	 	  	with a copy to:
		
	 	  	 John E. Tucker, Esq.
 825 Third Avenue
14th Floor
 New York, NY 10022

	 	  	Facsimile:	    	212-541-4434

  
 or at such other address as the
Company or the Purchaser may designate by written notice to the other parties hereto given in accordance herewith. 
  
 11.9 Attorneys’ Fees. In the event that any suit or action is instituted to enforce any provision in this Agreement, the prevailing party in
such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of such prevailing party under or with respect to this Agreement, including, without limitation, such reasonable fees and expenses of
attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals. 
  
 11.10 Titles and Subtitles. The titles of the sections and subsections of the Agreement are for convenience of reference only and are not to be
considered in construing this Agreement. 
  

 24 








 11.11 Facsimile Signatures; Counterparts. This Agreement may be executed by facsimile signatures
and in any number of counterparts, each of which shall be an original, but all of which together shall constitute one instrument. 
  
 11.12 Broker’s Fees. Except as set forth on Schedule 11.12 hereof, Each party hereto represents and warrants that no agent, broker, investment
banker, person or firm acting on behalf of or under the authority of such party hereto is or will be entitled to any broker’s or finder’s fee or any other commission directly or indirectly in connection with the transactions contemplated
herein. Each party hereto further agrees to indemnify each other party for any claims, losses or expenses incurred by such other party as a result of the representation in this Section 11.12 being untrue. 
  
 11.13 Construction. Each party acknowledges that its legal counsel
participated in the preparation of this Agreement and the Related Agreements and, therefore, stipulates that the rule of construction that ambiguities are to be resolved against the drafting party shall not be applied in the interpretation of this
Agreement to favor any party against the other. 
  
 [THE
REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK] 
  

 25 








 IN WITNESS WHEREOF, the parties hereto have executed the SECURITIES PURCHASE AGREEMENT as of the date set
forth in the first paragraph hereof. 
  

							
	COMPANY:	 	PURCHASER:
		
	ICORIA, INC.	 	LAURUS MASTER FUND, LTD.
				
	By:	 	 /s/ Philip R. Alfano
	 	By:	 	/s/ Eugene Grin
	Name:	 	 Philip R. Alfano
	 	Name:	 	Eugene Grin
	Title:	 	Vice President, Finance and CFO	 	Title:	 	Director

  

 26 








 EXHIBIT A 
  

FORM OF CONVERTIBLE NOTE 
  

 A-1 








 EXHIBIT B 
  

FORM OF WARRANT 
  

 B-1 








 EXHIBIT C 
  

FORM OF OPINION 
  

 C-1 








 EXHIBIT D 
  

FORM OF ESCROW AGREEMENT 
  

 D-2 








 SCHEDULES 
  

(Any Schedule Not Listed Has Been Intentionally Omitted) 
  
 SCHEDULE 4.3 
  
 CAPITALIZATION AND VOTING RIGHTS 
  
 Stonegate Securities, Inc. 
  
 Placement Agency Agreement, dated July 14, 2004, by and between Paradigm Genetics, Inc., a Delaware corporation, and Stonegate Securities, Inc., a Texas corporation. 
  
 TissueInformatics.Inc. Merger 
  
 On March 11, 2004, Paradigm Genetics, Inc. (now “Icoria, Inc.”) completed its acquisition of
TissueInformatics.Inc, a Delaware corporation. TissueInformatics merged with and into Paradigm with Paradigm continuing as the surviving corporation pursuant to the terms of an Agreement and Plan of Merger among Paradigm, TissueInformatics and TVM V
Life Science Ventures GmbH & Co., KG dated January 29, 2004 and as amended on March 10, 2004. 
  
 The transaction is more fully disclosed in reports filed pursuant to the Securities Exchange Act of 1934. See specifically, Form 8-K filed March 24, 2004
and the Form 10-K filed March 30, 2004.  
  
 Future
Amendments and Additions to Employee Stock/Option Plans 
  
 Pursuant to recent stockholder vote, additions to existing and additional stock plans will be registered. See definitive proxy statement filed March 31, 2004. 
  

 C-3 








 SCHEDULE 4.6 
  
 AGREEMENTS; ACTION 
  
 GE Prepayment 
  
 GE Healthcare Financial Services payoff letter dated October 15, 2004. 
  
 Stonegate Securities, Inc. 
  

Placement Agency Agreement, dated July 14, 2004, by and between Paradigm Genetics, Inc., a Delaware corporation, and Stonegate Securities, Inc., a
Texas corporation. 
  
 TissueInformatics.Inc. Merger

  
 On March 11, 2004, Paradigm Genetics, Inc. (now
“Icoria, Inc.”) completed its acquisition of TissueInformatics.Inc, a Delaware corporation. TissueInformatics merged with and into Paradigm with Paradigm continuing as the surviving corporation pursuant to the terms of an Agreement and
Plan of Merger among Paradigm, TissueInformatics and TVM V Life Science Ventures GmbH & Co., KG dated January 29, 2004 and as amended on March 10, 2004. 
  
 The transaction is more fully disclosed in reports filed pursuant to the Securities Exchange Act of 1934. See specifically, Form 8-K filed March 24, 2004
and the Form 10-K filed March 30, 2004.  
  
 Silicon
Valley Bank 
  
 Intercreditor Agreement between Silicon
Valley Bank and Laurus Master Fund regarding Silicon Valley Bank Loan and Security Agreement of July 10, 2003. 
  

 C-4 








 SCHEDULE 4.7 
  
 OBLIGATIONS TO RELATED PARTIES 
  
 TissueInformatics.Inc. Merger 
  
 On March 11, 2004, Paradigm Genetics, Inc. (now “Icoria, Inc.”) completed its acquisition of
TissueInformatics.Inc, a Delaware corporation. TissueInformatics merged with and into Paradigm with Paradigm continuing as the surviving corporation pursuant to the terms of an Agreement and Plan of Merger among Paradigm, TissueInformatics and TVM V
Life Science Ventures GmbH & Co., KG dated January 29, 2004 and as amended on March 10, 2004. 
  
 The transaction is more fully disclosed in reports filed pursuant to the Securities Exchange Act of 1934. See specifically, Form 8-K filed March 24, 2004
and the Form 10-K filed March 30, 2004.  
  
 SCHEDULE 4.8

  
 CHANGES 
  
 Routine IP Practice 
  
 Our routine practice in developing compounds and conducting research on
behalf of third parties requires us to assign certain intellectual property rights to those third parties. This is more fully described in our reports pursuant to the Securities Exchange Act of 1934. 
  
 SCHEDULE 4.13 
  
 TAX RETURNS AND PAYMENTS 
  
 TissueInformatics.Inc. Merger 
  
 There are outstanding tax filings due to merger. We anticipate making such
filings forthwith and that the cost will be primarily that of the process of filing. 
  

 C-5 








 SCHEDULE 4.14 
  
 EMPLOYEES 
  
 Future Amendments and Additions to Employee Stock/Option Plans 
  
 Pursuant to recent stockholder vote, additions to existing and additional stock plans will be registered. See definitive
proxy statement filed March 31, 2004. 
  
 SCHEDULE 4.15

  
 REGISTRATION RIGHTS AND VOTING RIGHTS

  
 Stonegate Securities, Inc. 
  
 Placement Agency Agreement, dated July 14, 2004, by and between Paradigm
Genetics, Inc., a Delaware corporation, and Stonegate Securities, Inc., a Texas corporation. 
  
 TissueInformatics.Inc. Merger 
  
 On March 11, 2004, Paradigm Genetics, Inc. (now “Icoria, Inc.”) completed its acquisition of TissueInformatics.Inc, a Delaware corporation. TissueInformatics merged with and into Paradigm with Paradigm continuing as the surviving
corporation pursuant to the terms of an Agreement and Plan of Merger among Paradigm, TissueInformatics and TVM V Life Science Ventures GmbH & Co., KG dated January 29, 2004 and as amended on March 10, 2004. 
  
 The transaction is more fully disclosed in reports filed pursuant to the
Securities Exchange Act of 1934. See specifically, Form 8-K filed March 24, 2004 and the Form 10-K filed March 30, 2004.  
  

 C-6 








 SCHEDULE 4.17 
  
 ENVIRONMENTAL AND SAFETY LAWS 
  
 Environmental 
  
 From time to time regulators review our facilities for our management of hazardous materials, including radioactive material, when issues are raised we
attempt to comply with regulators’ findings in a swift and thorough manner. We have not used radioactive material in our operations since September of 2003. We still maintain certain licensure for the use of certain radioactive material in case
a future project should require it. 
  
 As disclosed in our reports filed pursuant
to the Securities Exchange Act of 1934: 
  
 Environmental
Regulation 
  
 Our research and development activities
involve the controlled use of hazardous materials and chemicals. We are subject to federal, state and local laws and regulations governing the use, storage, handling and disposal of such materials and certain waste products. The risk of accidental
contamination or injury from these materials cannot be eliminated. In the event of an accident, we could be held liable for any damages that result, and any liability could exceed our resources. 
  
 SCHEDULE 11.12 
  
 BROKER’S FEES 
  
 Stonegate Securities, Inc. 
  
 Placement Agency Agreement, dated July 14, 2004, by and between Paradigm
Genetics, Inc., a Delaware corporation, and Stonegate Securities, Inc., a Texas corporation. 
  

 C-7